other two drugs (Stimulation Index to each drug, 2.03–2.10), it is likely that our patient was sensitized to all the drugs. Such ‘multiple drug hypersensitivity’ can be most efficiently proven by LTTs. Interestingly, such ‘multiple drug hypersensitivity’ was often observed associated with *mycoplasma pneumoniae* infection. No previous reports, however, described the occurrence of multiple drug hypersensitivity in patients with SARS-CoV-2 infection. A straightforward interpretation is that our patient could be immunologically sensitized to multiple medications probably due to preceding or underlying SARS-CoV-2 infection, although it remains unknown whether SARS-CoV-2 infection could serve to enhance the activation of drug-specific T cells with cross-reactive reactivity. Nevertheless, we cannot totally exclude the possibility that multiple drug sensitization proven solely by LTTs may be a mere epiphenomenon of the underlying SARS-CoV-2 infection.

In conclusion, we recommend that LTT tests be utilized in any patient with cutaneous manifestations of SARS-CoV-2 to exclude the possibility of drug sensitization. Multiple drug hypersensitivity is apparently under-reported because the diagnosis of SARS-CoV-2-induced rash is usually made without performing LTTs. If cutaneous symptoms were viewed as a mere manifestation of SARS-CoV-2 infection with no further search to identify drug hypersensitivity, then the disease would remain regarded as SARS-CoV-2-induced rash. Indeed, the presentation of our patient was consistent with symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). Although SDRIFE-like skin lesions have been reported as a cutaneous manifestation of COVID-19, a drug aetiology could have caused SDRIFE-like skin lesions in patients with SARS-CoV-2 infection.

**Acknowledgement**
The patient in this manuscript has given written informed consent to publication of his case details.

**Conflict of interest**
The authors have no conflict of interest to declare.

**Funding**
The article has no founding source.

J. Hayakawa,1,2 H. Takakura,2 Y. Mizukawa,1,3 T. Shiohara1,3,*

1Division of Dermatology, Kosei Hospital, Tokyo, Japan, 2Division of Respiratory medicine, Kosei Hospital, Tokyo, Japan, 3Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

*Correspondence: J. Hayakawa. E-mail: jun.hayakawa@kosei-hp.or.jp

[Correction added on 14 October 2020, after first online publication: ORCID of authors ‘H.Takakura’ and ‘T.Shiohara’ have been added to this version.]

---

**References**

1 Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue. *Br J Dermatol* 2020; 183: 71–77. https://doi.org/10.1111/bjd.19264

2 Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. *J Eur Acad Dermatol Venereol* 2020; 34: e306–e307. https://doi.org/10.1111/jdv.16530

3 Wollina U, Karadag AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 Patients: A review. *Dermatol Ther* 2020; e13594, 1–6.

4 Mockenhaupt M, Vihoud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The Euro SCSR-study. *J Invest Dermatol* 2008; 128: 35–44.

5 Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy* 2004; 59: 809–820.

6 Aoyama Y, Sawada F, Makino E, Shiohara T. Multiple drug sensitization syndrome: A distinct phenotype associated with unrecognized *mycoplasma pneumoniae* infection. *JAAD Case Rep* 2017; 3: 301–305.

7 Takahashi R, Kano Y, Yamazaki Y et al. Defective regulatory T cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome. *J Immunol* 2009; 182: 8071–8079.

8 Weiss D, Kinaciyan T. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mefenamic acid. *JAAD Case Rep* 2019; 5: 89–90.

9 Mahe A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with Coronavirus Disease 2019? *J Eur Acad Dermatol Venereol* 2020; 34: e246–e247.

DOI: 10.1111/jdv.16878

---

**Scabies outbreak during home confinement due to the SARS-CoV-2 pandemic**

**Editor**

In response to the rapid spread of COVID-19 at the start of the pandemic, governments introduced severe measures of home confinement and isolation of the population in an effort to prevent their health systems from collapsing. On March 14, with more than 4000 confirmed cases, Spain began its nationwide lockdown which has extended for almost three months.

In recent weeks, numerous articles have reported a wide range of skin symptoms of COVID-19, but there are other dermatological conditions that may have been aggravated during this global pandemic. Scabies is a highly contagious skin infestation caused by the mite *Sarcoptes scabiei* (*variety hominis*). In developed countries, scabies is usually observed sporadically or as institutional outbreaks in hospitals, nursing homes, prisons, long-term care facilities or in displaced persons and asylum seekers. However, we have observed a significant increase of scabies cases in our region during the confinement period (March, April and May 2020) compared to the average for the same period during the previous five years (64 vs. 18.6 patients).
In an attempt to analyse how the confinement had influenced the scabies infestation, we have compared the characteristics of the patients diagnosed by dermatologists (based on clinical and dermatoscopic criteria) in that quarter during the last five years with those diagnosed during the confinement (Table 1). The lockdown changed not only the number of patients infested, but also the features of the disease and our management (Fig. 1). First, spending more time at home and therefore with relatives, increases the risk of transmitting the parasite through direct contact or by fomites, a rise that has also been observed during the winter season. Second, we observed that during the period of confinement, the duration of symptoms reported by patients was significantly longer. This seems to be explained by the population’s fear of leaving home unless it was strictly necessary, not seeking medical attention until they got desperate by the pruritus. The detection and treatment of the index case is the most effective measure to stop scabies spread, and this delay in diagnosis may have led to an increased intrafamilial transmission in our sample, as it is described in other studies. The proportion of patients with history of family members or cohabitants diagnosed with scabies (or suspected) was significantly higher in the confinement group, reaching more than the 80%; and more than the half of our sample consulted the dermatologist with their cohabitants, conforming ‘family clusters’, while only a 20% did in the non-confinement group.

Regarding to treatment, all members of our sample were treated with topical 5% permethrin cream, as it is the first-line treatment in our country; however, there is a higher proportion of

---

**Table 1** Comparison of demographic, clinical and therapeutic data between scabies cases diagnosed during the months of confinement and non-confinement

|                               | Confinement† | No confinement‡ | Statistical comparison |
|-------------------------------|--------------|----------------|------------------------|
| N                             | 64           | 93             |                        |
| Gender                        |              |                |                        |
| Male                          | 32           | 48             |                        |
| Female                        | 32           | 45             |                        |
| Age (mean ± SD)               | 30.87 ± 21.28| 32.16 ± 25.11  | t(155) = −0.336, P > 0.05|
| Cohabitants                   | 52 (81.25%)  | 61 (65.59%)    |                        |
| Family Cluster                | 35 (54.68%)  | 18 (19.35%)    | χ² (1) = 3.865, P < 0.05|
| Symptoms duration             | 9.75 ± 5.85  | 5.77 ± 5.172   | t(1154) = 4.47, P < 0.05|
| Previous treatment            | 48 (75%)     | 14 (15.05%)    |                        |
| Treatment with permethrin     | 64 (100%)    | 93 (100%)      |                        |
| Previous applications of permethrin (mean ± SD) | 4.10 ± 2.94 | 1.64 ± 0.84    | t(59.9) = −5.123, P < 0.05|
| Treatment with ivermectin     | 36 (60.93%)  | 4 (4.3%)       | χ² (1) = 58.33, P < 0.05|

†Period between March and May 2020.
‡Period between March and May from 2015 to 2019.

---

**Figure 1** Home confinement effect on scabies infestation.
patients who had already been treated by their primary healthcare providers during confinement because general practitioners made an effort to avoid hospital referral of non-urgent conditions due to the public health situation. In addition, the number of permethrin applications in confined patients was significantly superior, and therefore, this group ended requiring oral treatment with ivermectin more frequently. Permethrin failure has often been observed in major outbreaks in institutions, due to complications in carrying out decontamination measures or in completing topical treatment, with frequent reinfections among cohabitants. On these occasions, oral treatment with ivermectin is considered as the first choice for controlling infestation.\textsuperscript{4,8,9} In our opinion, during home confinement, minor outbreaks have arisen within each family group, and management difficulties are similar to those previously mentioned for institutional outbreaks, so perhaps the approach should be similar.

The results presented are from a single hospital in Spain, and these results cannot be generalized; however, due to the dramatic evolution of the pandemic, we could suffer again a confinement and this work provides a basis for future researchers to implement and evaluate preventive actions to reduce and recognize early cases of scabies in this context.

\textbf{Conflict of interest}

None declared.

\textbf{Funding sources}

There has been no financial support for this work that could have influenced its outcome.

I. Martínez-Pallás,\textsuperscript{1,*} B. Aldea-Manrique,\textsuperscript{1} M. Ramírez-Lluch,\textsuperscript{1} J. Manuel Vinuesa-Hernando,\textsuperscript{2} M. Ara-Martín\textsuperscript{1}

\textsuperscript{1}Department of Dermatology, Lozano Blesa Clinical Hospital, 15th San Juan Bosco Ave, Zaragoza, Spain
\textsuperscript{2}Pharmacy Department, Lozano Blesa Clinical Hospital, 15th San Juan Bosco Ave, Zaragoza, Spain

*Correspondence: I. Martínez-Pallás. E-mail: imartinezp@salud.aragon.es

\section*{References}

1. Informe COVID-19 n° 9. 13 de marzo de 2020. Ministerio de Sanidad; 2020.
2. Wolfin U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: a review [published online ahead of print, 2020 May 10]. Dermatol Ther 2020; e13549. https://doi.org/10.1111/dth.13549
3. Micali G, Lacarubba F, Verzi AE, Chosidow O, Schwartz RA. Scabies: advances in noninvasive diagnosis. PlOS Negl Trop Dis 2016; 10: e0004691.
4. Thean LJ, Engelman D, Kaldor J, Steer AC. Scabies: new opportunities for management and population control. Pediatr Infect Dis J 2019; 38: 211–213.
5. Mueller SM, Gysin S, Schweitzer M et al. Implementation and evaluation of an algorithm for the management of scabies outbreaks. BMC Infect Dis 2019; 19: 290.
6. de Beer G, Miller MA, Tremblay L, Monette J. An outbreak of scabies in a long-term care facility: the role of misdiagnosis and the costs associated with control. Infect Control Hosp Epidemiol 2006; 27: 517–518.
7. Ariza L, Walter B, Worth C, Brockmann S, Weber ML, Feldmeier H. Investigation of a scabies outbreak in a kindergarten in Constance, Germany. Eur J Clin Microbiol Infect Dis 2013; 32: 373–380.
8. Sunderkötter C, Feldmeier H, Fölster-Holst R et al. S1 guidelines on the diagnosis and treatment of scabies – short version. J Dtsch Dermatol Ges 2016; 14: 1155–1167.
9. Middleton J, Walker SL, House T, Head MG, Cassel JA. Ivermectin for the control of scabies outbreaks in the UK. Lancet 2019; 394: 2068–2069.

\textbf{DOI: 10.1111/jdv.16879}

\section*{Acral skin eruption observed during SARS-CoV-2 pandemic: possible keratolysis exfoliativa with red palms and soles}

\textbf{Editor},

Chilblain-like\textsuperscript{1-3} and erythema multiforme-like\textsuperscript{4} lesions represent the most reported and studied acral skin eruptions occurring in the paediatric age during the SARS-CoV-2 pandemic. In the same period, we observed a peculiar acral eruption in paediatric patients. Five children (4 females and 1 male) aged from 1 to 4 years (mean age: 3 years) presented erythema and oedema involving the palmar (5/5 cases) and plantar (3/5) surfaces. The most affected sites were thenar and hypothenar areas, and the fingertips. After some days, an intense superficial desquamation with a centrifugal pattern of expansion occurred (Fig. 1). The symptoms referred were itching (5/5), pain (1/5) and burning sensation (1/5). In 2/5 cases, fever (38–39°C) preceded the acral eruption, while a diffuse maculopapular rash occurred in 2/5

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{acral_skin_eruption.png}
\caption{Symmetrical redness of the palms and the fingertips, with multiple round areas of superficial desquamation.}
\end{figure}